Xentria’s XTMAB-16 Receives Orphan Drug Designation From EMA
Xentria’s bid to find a new use for TNF inhibitors has landed it with $45 million in the bank. Building on evidence that Remicade improves outcomes in a lung disease, Xentria has persuaded Meitheal Pharmaceuticals to hand over the upfront payment and offer more than $600 million in potential future paydays for North American rights to its candidate.
Xentria Announces Peer Reviewed Publication of Biosimulation Model in Frontiers in Pharmacology Journal
CHICAGO--(BUSINESS WIRE)--Xentria Inc., a biotech company focused on developing novel therapeutics to address unmet clinical needs, made key leadership appointments, naming Dr. Robert Baughman as Lead Scientific Advisor and Kirsten Anderson as Chief Operating Officer.
CHICAGO--(BUSINESS WIRE)--Xentria Inc., a biotech company focused on developing novel biologics to address unmet clinical needs, presented its first set of data showing its novel biologic, XTMAB-16, has the potential to reduce the formation of sarcoidosis granulomas.